Intercept CEO lays into FDA after NASH drug rejectionIntercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty Share XIntercept CEO lays into FDA after NASH drug rejectionhttps://pharmaphorum.com/news/intercept-ceo-lays-into-fda-after-nash-drug-rejection/
